However, the use of bronchodilators as preexisting medication on sepsis onset was significantly higher in TIM-3 rs1036199 AA homozygous patients compared to C-allele carriers (13% vs. 6%; p = 0.0052; Table 1) and in TIM-3 rs10515746 CC homozygous patients compared to A-allele carriers (12% vs. 6%; p = 0.0155; Table 2). This evidence concerns the gene HAVCR2 and Sepsis.